Awareness, Care & Treatment In Obesity Management - An Observation in Switzerland (ACTION-CH)

ACTION Switzerland is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product. Collection of data will be performed via quantitative online survey by a third-party vendor.

The goal of this study is to provide insights to drive awareness around the needs of People Living with Obesity (PLwO) and Health Care Professionals (HCPs) involved in obesity treatment and management.

Study Overview

• Status: Completed
• Conditions: Obesity
• Intervention / Treatment: Other: No treatment given

• Study Type: Observational
• Enrollment (Actual): 1152

Contacts and Locations

Study Locations

• Switzerland
  • Zürich, Switzerland
    • Novo Nordisk Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The respondent population will include people living with obesity (PLwO) and health care professionals (HCPs) involved in obesity treatment and management

Description

Inclusion criteria:

People Living with Obesity:

1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
2. Male, female or other, aged above or equal to 18 years at the time of signing informed consent
3. Lives in Switzerland (minimum quota based on primary language: German, French and Italian to ensure adequate samples for sub-group analysis)
4. Current BMI of 30 Kg/m^2 or greater calculated based on self-reported height and weight

Health Care Professionals:

1. Informed consent before any study related activities (study-related activities are any procedure related to recording/collection of data according to protocol)
2. Male, female or other, aged above or equal to 18 years at the time of signing informed consent.
3. Physician
4. Dietitian who is a member of the SVDE ASDD (Swiss Association of Dietitians) and services covered by the compulsory health insurance
5. Primary Care Providers (PCPs) whose specialty is Family Practice, General Practice, General Internal Medicine (who is focused on primary care)
6. Non-PCP Specialties whose specialty is Obstetrics/Gynaecologists, Endocrinologists/Diabetologists. Psychiatrists, General Internal Medicine with focus on diabetes and/or obesity and bariatric surgeons who are involved in the management of obesity in addition to surgery
7. Practices in Switzerland
8. In clinical practice for greater than or equal to 2 years
9. Spends at least 50% time in direct patient care
10. Has seen at least 100 adult patients in past month (all physicians except psychiatrists) Has seen at least 10 patients with obesity (PCPs and General Internal Medicine with focus on Diabetes and/or obesity, Obstetrics/ Gynaecologists, Endocrinology/Diabetology or Bariatric surgery) or 5 patients with obesity (dietitians and psychiatrists) in past month needing weight management defined as: a patient with a BMI greater than or equal to 30 Kg/m^2 with or without comorbidities.

Exclusion criteria:

People Living with Obesity:

1. Previous participation in this study. Participation is defined as having given online consent in this study
2. Currently pregnant
3. Participates in intense fitness or body building programs
4. Has had significant, unintentional weight loss (due to major injury, illness, etc) in the past 6 months
5. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Health Care Providers:

1. Previous participation in this study. Participation is defined as having given informed consent in this study.
2. Unwillingness, inability, or language barriers precluding adequate understanding or cooperation.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
People / Person Living with Obesity (PLwO); From online, general population consumer panels	Other: No treatment given; No treatment given
Health Care Professionals (HCPs); HCPs treating people who have obesity	Other: No treatment given; No treatment given

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of PLwO who made serious weight loss effort	Number of weight loss efforts; percentage of patients	At the time of survey response (Day 1)
Weight loss motivators	Multi-select from defined list	At the time of survey response (Day 1)
Attitudes towards obesity and weight management and Interactions of PLwOs with HCPs	5-point Likert scales (e.g., agreement, impact, frequency) - Proportion of responses in each category will be reported.	At the time of survey response (Day 1)
Weight loss barriers	Multi-select from defined list	At the time of survey response (Day 1)
Weight loss management	Multi-select from defined list	At the time of survey response (Day 1)

Collaborators and Investigators

• Sponsor: Novo Nordisk A/S

Study record dates

Study Major Dates

• Study Start (Actual): March 8, 2022
• Primary Completion (Actual): April 8, 2022
• Study Completion (Actual): April 8, 2022

Study Registration Dates

• First Submitted: January 12, 2022
• First Submitted That Met QC Criteria: February 9, 2022
• First Posted (Actual): February 10, 2022

Study Record Updates

• Last Update Posted (Actual): October 26, 2022
• Last Update Submitted That Met QC Criteria: October 25, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Overweight; Body Weight; Obesity
• Other Study ID Numbers: DAS-005; U1111-1266-4398 (Other Identifier: World Health Organization (WHO))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

• Studies a U.S. FDA-regulated device product: No